126 related articles for article (PubMed ID: 38625730)
1. Clinical Efficacy and Safety of Intravenous Ferric Carboxymaltose for Treatment of Restless Legs Syndrome: A Multicenter, Randomized, Placebo-controlled Clinical Trial.
Earley CJ; García-Borreguero D; Falone M; Winkelman JW
Sleep; 2024 Apr; ():. PubMed ID: 38625730
[TBL] [Abstract][Full Text] [Related]
2. Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia.
Bae H; Cho YW; Kim KT; Allen RP; Earley CJ
Sleep Med; 2021 Aug; 84():179-186. PubMed ID: 34157632
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial.
Allen RP; Adler CH; Du W; Butcher A; Bregman DB; Earley CJ
Sleep Med; 2011 Oct; 12(9):906-13. PubMed ID: 21978726
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ferric carboxymaltose (FCM) 500 mg dose for the treatment of Restless Legs Syndrome.
Cho YW; Allen RP; Earley CJ
Sleep Med; 2018 Feb; 42():7-12. PubMed ID: 29458749
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome.
Cho YW; Allen RP; Earley CJ
Sleep Med; 2016 Sep; 25():16-23. PubMed ID: 27823710
[TBL] [Abstract][Full Text] [Related]
6. Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome.
Schneider J; Krafft A; Manconi M; Hübner A; Baumann C; Werth E; Gyr T; Bassetti C
Sleep Med; 2015 Nov; 16(11):1342-1347. PubMed ID: 26498233
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of intravenous ferric carboxymaltose treatment for restless legs symptoms and low serum ferritin in children with autism spectrum disorder.
DelRosso LM; Reuter-Yuill LM; Cho Y; Ferri R; Mogavero MP; Picchietti DL
Sleep Med; 2022 Dec; 100():488-493. PubMed ID: 36265207
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome.
Lee DO; Buchfuhrer MJ; Garcia-Borreguero D; Avidan AY; Ahmed M; Hays R; Ondo WG; Jaros MJ; Kim R; Shang G
Sleep Med; 2016 Mar; 19():50-6. PubMed ID: 27198947
[TBL] [Abstract][Full Text] [Related]
9. Patient characteristics predicting responses to intravenous ferric carboxymaltose treatment of restless legs syndrome.
Park HR; Choi SJ; Joo EY; Allen RP
Sleep Med; 2020 Nov; 75():81-87. PubMed ID: 32853922
[TBL] [Abstract][Full Text] [Related]
10. Iron for the treatment of restless legs syndrome.
Trotti LM; Becker LA
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD007834. PubMed ID: 30609006
[TBL] [Abstract][Full Text] [Related]
11. Dose response of Gabapentin Enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies.
VanMeter SA; Kavanagh ST; Warren S; Barrett RW
CNS Drugs; 2012 Sep; 26(9):773-80. PubMed ID: 22849331
[TBL] [Abstract][Full Text] [Related]
12. Ferric carboxymaltose effects on restless legs syndrome and on brain iron in patients with iron deficiency anemia.
Bae H; Cho YW; Kim KT; Li X; Earley CJ
Sleep Med; 2023 Sep; 109():128-131. PubMed ID: 37437492
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome.
Lee DO; Ziman RB; Perkins AT; Poceta JS; Walters AS; Barrett RW;
J Clin Sleep Med; 2011 Jun; 7(3):282-92. PubMed ID: 21677899
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder.
DelRosso LM; Ferri R; Chen ML; Kapoor V; Allen RP; Mogavero MP; Picchietti DL
Sleep Med; 2021 Nov; 87():114-118. PubMed ID: 34562823
[TBL] [Abstract][Full Text] [Related]
15. Does Repeated Dosing of Intravenous Ferric Carboxymaltose Alleviate Symptoms of Restless Legs Syndrome?
Park HR; Choi SJ; Joo EY
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329998
[TBL] [Abstract][Full Text] [Related]
16. Effect of Gabapentin Enacarbil on Individual Items of the International Restless Legs Study Group Rating Scale and Post-sleep Questionnaire in Adults with Moderate-to-Severe Primary Restless Legs Syndrome: Pooled Analysis of 3 Randomized Trials.
Ahmed M; Hays R; Steven Poceta J; Jaros MJ; Kim R; Shang G
Clin Ther; 2016 Jul; 38(7):1726-1737.e1. PubMed ID: 27288210
[TBL] [Abstract][Full Text] [Related]
17. Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire.
Allen R; Oertel W; Walters A; Benes H; Schollmayer E; Grieger F; Moran K; Kohnen R
Sleep Med; 2013 Dec; 14(12):1375-80. PubMed ID: 24246378
[TBL] [Abstract][Full Text] [Related]
18. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension.
Giorgi L; Asgharian A; Hunter B
Clin Ther; 2013 Sep; 35(9):1321-36. PubMed ID: 23938061
[TBL] [Abstract][Full Text] [Related]
19. Post Hoc Analysis of Data from Two Clinical Trials Evaluating the Minimal Clinically Important Change in International Restless Legs Syndrome Sum Score in Patients with Restless Legs Syndrome (Willis-Ekbom Disease).
Ondo WG; Grieger F; Moran K; Kohnen R; Roth T
J Clin Sleep Med; 2016 Jan; 12(1):63-70. PubMed ID: 26446245
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.
Kushida CA; Becker PM; Ellenbogen AL; Canafax DM; Barrett RW;
Neurology; 2009 Feb; 72(5):439-46. PubMed ID: 19188575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
